Connect with us

Technology

FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study

Published

on

Azenta will provide proteomics technology profiling on up to 20,000 individuals.

BURLINGTON, Mass., July 22, 2024 /PRNewswire/ — Azenta, Inc. (Nasdaq: AZTA) today announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland. The FinnGen project is a pioneering endeavor that has collected and is currently analyzing genomic and health data from a cohort of 500,000 Finnish biobank participants.

In collaboration with the University of Helsinki, the organization leading the FinnGen study, Azenta will provide comprehensive proteomics profiling on up to 20,000 individuals, underscoring Azenta’s commitment to advancing healthcare innovation and personalized treatments. Azenta will use Olink’s advanced proteomics technology, based on the proprietary Proximity Extension Assay, to provide high-quality protein-level measurements across all major biological pathways.

“FinnGen’s adoption of proteomics marks a pivotal advancement in our quest to decode the complexities of human health and disease. By integrating the dynamic insights of proteomics with our extensive genomic data, we can gain a deeper understanding of disease mechanisms, identify new biomarkers for early detection, and uncover novel therapeutic targets. We are pleased to collaborate with Azenta Life Sciences, and trust that they will provide excellent service and deliver high-quality proteomic data with a fast turnaround time,” said Professor Aarno Palotie, FinnGen Scientific Director from the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. “Combined with excellent quality and reliable results, Azenta Life Sciences can help us construct a strong foundation for advancing the field of personalized medicine.”

“As one of the collaborators in the FinnGen Project, Azenta looks forward to making meaningful contributions to personalized medicine and revolutionizing healthcare for generations to come,” said Ginger Zhou, PhD., Senior Vice President and General Manager, GENEWIZ Multiomics & Synthesis Solutions from Azenta Life Sciences. “Multiomics technologies from Azenta enable researchers to efficiently generate detailed proteomics data from study participants carrying medically and clinically significant genetic variants, opening up a world of possibilities for understanding disease mechanisms and developing targeted treatments.”

About FinnGen

FinnGen is a large public-private partnership aiming to collect and analyze genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.

For more information, please visit https://www.finngen.fi/en.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry’s top pharmaceutical, biotech, academic, and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta’s financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Other forward-looking statements include but are not limited to statements about the prospects of the FinnGen Project and our ability to contribute to the advancement of personalized medicine. Factors that could cause results to differ from our expectations include the following: changes in technology and/or science that impact our ability to enable researchers to generate the proteomics data required to understand disease and develop targeted treatments and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com

Sherry Dinsmore
sherry.dinsmore@azenta.com

Azenta’s use of third-party trademarks and brands are for identification only and does not imply affiliation or endorsement. All trademarks used herein are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/finngen-selects-azenta-to-propel-personalized-medicine-for-population-health-study-302203113.html

SOURCE Azenta

Continue Reading

Technology

goeasy Ltd. Announces Voting Results from Special Meeting of Shareholders

Published

on

By

MISSISSAUGA, ON, Nov. 3, 2026 /CNW/ — goeasy Ltd. (TSX: GSY) (“goeasy” or the “Company”), one of Canada’s leading consumer lenders focused on delivering a full suite of financial services to Canadians with non-prime credit scores, announced today that its shareholders passed the resolution ratifying, confirming and approving the Company’s Shareholder Rights Plan adopted by the Company’s Board of Directors on May 12, 2026. The vote was conducted at the Company’s Special Meeting of Shareholders which took place on November 3, 2026. The results of the vote are set out below:

Number of Shares

Voted For

Percentage of

Votes Cast

Number of

Shares Voted

Against

Percentage of

Votes Cast

8,164,270

98.926 %

88,625

1.074 %

A full report on voting results is available under goeasy’s profile on SEDAR+ at www.sedarplus.ca.

About goeasy

goeasy Ltd. is a leading Canadian provider of non-prime consumer lending solutions, offering a suite of financial products through its easyfinancial, easyhome, and LendCare brands. goeasy offers unsecured and secured instalment loans, point-of-sale financing, and lease-to-own merchandise through its omni-channel model, which spans online, mobile, and hundreds of locations nationwide.

Driven by its team members’ dedication to expand access to credit for underserved communities and helping customers strengthen their financial futures, goeasy has proudly served more than 1.6 million customers while building an award-winning culture. Shares of goeasy Ltd. are listed on the Toronto Stock Exchange (TSX) under the symbol GSY. For more information, visit www.goeasy.com.

For investor inquiries, contact:

James Obright
Senior Vice President, Investor Relations & Capital Markets
investor_relations@goeasy.com

For media inquiries, contact:

mediainquiries@goeasy.com

SOURCE goeasy Ltd.

Continue Reading

Technology

Saigon Technology: Why Businesses Fear Modernizing Software in the AI Era

Published

on

By

SYDNEY, Nov. 4, 2026 /PRNewswire/ — Modernizing an entire software system often leaves businesses with two choices: invest heavily in an in-house team for a project that may not require the same resources later, or work with an experienced partner that already has the expertise in place.

While outsourcing offers greater flexibility, it also raises concerns about data security, business disruption, and finding a partner capable of handling complex systems.

Saigon Technology, an award-winning software engineering company with an AI-native delivery approach, believes businesses shouldn’t have to sacrifice security or stability to modernize. With the right partner, they can move forward while keeping everything under control.

66% of Australian Enterprises Lack Full Data Access Visibility

At many businesses, the existing systems may hold customer records, financial data, and core business processes. Giving a partner full access can create risks that businesses are not willing to take.

But modernization does not always require handing over the keys to the entire system.

Instead, companies can limit access to specific parts of their software, keep sensitive data in protected environments, and require approval before major changes are made. External engineers can work with test data or selected modules while the business keeps control of its main systems.

This allows businesses to gain the skills they need without giving up oversight of their most valuable technology assets.

Then Comes the Fear of Disruption

Data security is only half the concern. What happens if a system upgrade interrupts orders, payments, or customer services? For businesses that rely on software every day, even a short disruption can affect customers, staff, and revenue.

Yet upgrading software does not always mean shutting down the old system and moving everything to a new one overnight.

A safer approach is to make changes step by step. Parts of the system can be upgraded while the rest continues running. Old and new systems may also run side by side, giving teams time to test changes, check data, and fix issues before a full switch.

With clear backup and recovery plans, businesses can reduce risk and maintain essential services throughout the process.

The Way Forward: Modernize Without Losing Control

These concerns raise a key question: how can businesses move faster without taking on more risk? The answer lies in choosing a development partner that works within the client’s rules, rather than asking the client to give up control.

Saigon Technology takes a security-focused approach to enterprise software modernization. Depending on project needs, its engineering teams can apply multi-factor authentication (2FA), data encryption, VPN-secured access, and role-based permissions to protect sensitive information. With 3 development centers in Vietnam, the company also brings the engineering expertise and capacity needed to upgrade critical systems while minimizing disruption to daily operations.

Saigon Technology holds ISO/IEC 27001:2022 certification for information security management and ISO 9001:2015 certification for quality management, reinforcing its commitment to secure software delivery.

“Businesses should not have to choose between keeping their systems safe and moving forward with new technology. A good engineering partner helps them do both, without putting daily operations at unnecessary risk.” Shared by Thanh Pham, CEO of Saigon Technology.

As AI creates new opportunities, Saigon Technology believes the businesses best placed to benefit will be those that can embrace change without losing control of what already works.

About Saigon Technology

Saigon Technology is an AI-driven software engineering company with over 400 engineers. Serving clients across Australia and global markets, the company combines AI expertise, secure engineering, and flexible delivery models to build sustainable digital solutions.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/saigon-technology-why-businesses-fear-modernizing-software-in-the-ai-era-302927193.html

SOURCE Saigon Technology

Continue Reading

Technology

I AM ALS COMMUNITY CELEBRATES AS ACT FOR ALS BECOMES LAW AND MAKES HISTORY

Published

on

By

Community Advocates, Including Co-Founders Brian Wallach and Sandra Abrevaya and I AM ALS Ambassadors Late Actor Eric Dane and Former Pro Wrestler Tanea “Rebel” Brooks, Drive Landmark Win Securing Up to $500 Million in Funding and Therapy Access, and a Continued Path to a Cure

Download Photos/Logo Here
I AM ALS Celebration Video for ACT for ALS

WASHINGTON, Nov. 3, 2026 /PRNewswire/ — I AM ALS and its national force of advocates are celebrating as the President signed the ACT for ALS reauthorization bill into law. This comes after the Senate approved the bill by unanimous consent with just hours left until the law expired, even after the House went home early. The I AM ALS community first identified a major gap in access to investigational treatments and co-authored the original ACT for ALS Act to address it in 2021. Now, with years of success underway, the law has five more years to scale research infrastructure and treatment access, representing an investment of up to an additional $500 million for ALS.

“Over the past 7+ years, this community has changed what’s possible in ALS,” said I AM ALS co-founder Brian Wallach. “The I AM ALS community’s leadership has brought us closer than ever to a cure by unlocking over $2 billion for federal ALS research, expanding and protecting access to life-changing therapies, and accelerating scientific breakthroughs. We thank our ALS congressional champions—including sponsors Senators Coons (D-DE) and Murkowski (R-AK) and Representatives Quigley (D-IL-05) and Calvert (R-CA-41)—and all the tireless advocates who helped renew this historic legislation for five more years.”

Today’s law passage is groundbreaking and thanks to the significant efforts of I AM ALS’ community-led movement. Since ACT for ALS was first signed into law, I AM ALS has monitored and reported on the ground-breaking success of its implementation. Leading into the reauthorization year, I AM ALS built and deployed a comprehensive, multi-pronged advocacy campaign, including:

Building and strengthening relationships with Congressional champions,Deploying a vast grassroots army of volunteer leaders from across the country,Partnering with researchers, other organizations, and celebrity ambassadors—most notably the late actor Eric Dane and professional wrestler Tanea “Rebel” Brooks—to strengthen and amplify our message, andEngaging with top experts in government affairs and public relations.

This year alone, I AM ALS held more than 430 in-person and virtual advocacy meetings and calls, secured more than 38,000 online actions, sent more than 95,000 emails, and gathered more than 20,100 petition signatures in the final weeks before expiration.

Unlike any other legislation the neurodegenerative landscape has ever seen, ACT for ALS has already invested hundreds of millions of dollars into ALS research, provided investigational therapy access for more than 800 patients who would not otherwise have qualified, and built lasting infrastructure for future learnings.

“These past months didn’t just get a critical bill passed; they inspired a community that continually renews itself, welcomes new advocates, develops new leaders, and ensures that every generation is ready to fight for the next breakthrough,” said Troy Fields, volunteer co-chair of the I AM ALS legislative affairs team, and person living with ALS. “ALS is relentless, but we continue to prove so are we.”

“For the past five years, the ACT for ALS has advanced scientific research and helped people with ALS access the promising treatments they need. This reauthorization of the bill continues that work and lends hope to a future where there is a cure for ALS,” said Congressman Quigley. “I’m glad this important bill was signed into law, and I’m thankful to my colleagues in both the House and the Senate for getting this done.”

“I’m thrilled that the ACT for ALS Reauthorization Act has been signed into law, renewing our commitment to finding cures and treatments for ALS,” said Rep. Calvert. “As a Co-Chair of the bipartisan ALS Caucus, I know just how hard those impacted by ALS have worked to get this bill enacted and I applaud their tireless advocacy. With the ACT for ALS Reauthorization Act officially signed into law, we celebrate this victory while remaining focused on the work ahead to end this terrible disease.”

I AM ALS is calling on supporters to thank the Congressional champions who helped make this law possible at bit.ly/A4A-TY 

About I AM ALS

I AM ALS is a nonprofit organization leading what STAT News called the most successful patient advocacy campaign this century. We built a community movement to harness collective power and find treatments and a cure for ALS faster, while also creating lasting, systemic change. Our focus is on three areas:

Advocating for federal policy change to drive research, support, and treatments for ALS.Improving quality of life by providing volunteer and support opportunities to advocates and people living with ALS.Mobilizing and empowering advocates to raise awareness about ALS and other neurodegenerative diseases, and increase visibility of the ALS experience.

Learn more at www.iamals.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-am-als-community-celebrates-as-act-for-als-becomes-law-and-makes-history-302928523.html

SOURCE I AM ALS

Continue Reading

Trending